Form 4: Glaukos Corp Chairman & CEO Thomas Burns Acquires Shares and Options Following Achievement of Operational Targets

Thomas Burns, Chairman & CEO of Glaukos Corp, reports acquisition of shares and options due to the achievement of pre-determined operational targets, as determined by the Compensation, Nominating and Governance Committee.

Summary

• Thomas Burns, the Chairman & CEO of Glaukos Corporation, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On September 19, 2024, Burns acquired 8,336 shares of common stock and options for 16,832 shares as part of a previously granted award of restricted stock units and options.
• The acquisition was triggered by the achievement of certain pre-determined operational targets over a multi-year performance period, as determined by the Compensation, Nominating and Governance Committee of Glaukos' Board of Directors.
• The shares and options will vest in installments, with 25% vesting in September 2024, December 2024, May 2025, and September 2025.
• Following the reported transactions, Burns directly owns 88,494 shares of common stock and indirectly owns a significant number of shares through various trusts.
• Burns also directly owns 69,432 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the achievement of operational targets triggered the vesting of shares and options, indicating progress and alignment of management incentives.

Positives

• The achievement of operational targets is a positive indicator of the company's performance.
• The vesting schedule incentivizes continued performance and alignment with shareholder interests.
• The CEO's increased stake in the company demonstrates confidence in its future prospects.

Future Outlook

The vesting schedule for the acquired shares and options extends into September 2025, suggesting a continued focus on achieving operational targets.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates that Glaukos has met certain internal performance benchmarks.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the medical device industry, aligning management incentives with shareholder value.
• The vesting schedule is typical for such grants, encouraging long-term commitment and performance.
• Comparable companies such as STAAR Surgical and Aerie Pharmaceuticals also utilize stock options and RSUs in their executive compensation packages.

Stakeholder Impact

• Shareholders may view the achievement of operational targets and the increased stake of the CEO as positive signals.
• Employees may be motivated by the company's success in meeting its targets.

Key Dates